Number one, we just need to keep describing it because when I talk to even oncologists who don’t specialize in kidney cancer, but especially people in research or pharma, they don’t really realize that there are so many patients undergoing active surveillance with metastatic disease. They have stage four disease and we’re not actively treating it. So number one, it’s getting the message out there...
Number one, we just need to keep describing it because when I talk to even oncologists who don’t specialize in kidney cancer, but especially people in research or pharma, they don’t really realize that there are so many patients undergoing active surveillance with metastatic disease. They have stage four disease and we’re not actively treating it. So number one, it’s getting the message out there. The clinical trials, you know, and for good reasons, are focused on treatment. And so that could lead one to assume that everyone gets treatment. So number one, it’s just kind of getting the message out there. But number two, you know, the next steps are really following these patients longitudinally and seeing how they do. We already have, you know, prior analyses from prior iterations of this observational study that have been included in the NCCN guidelines supporting, you know, that active surveillance may be appropriate for certain patients. So the next steps will really be describing their longitudinal patient-reported outcomes and then also overall survival, the time to when they need systemic therapy if they need it. And then I think kind of next steps after that would be looking at biomarkers. We are collecting baseline blood and we have the ability to collect imaging and tissue biomarkers as well. So really understanding who could benefit at a molecular level I think would also be a benefit.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
